AAT augmentation therapy is a treatment designed for individuals with Alpha-1 Antitrypsin Deficiency, a genetic condition that can lead to lung and liver disease. This therapy involves administering Alpha-1 Antitrypsin protein, which helps protect the lungs from damage caused by enzymes released during inflammation. By increasing the levels of this protein in the bloodstream, the therapy aims to slow the progression of lung disease. The treatment is typically given through intravenous infusions and is usually administered once a week. While AAT augmentation therapy does not cure the deficiency, it can improve lung function and quality of life for those affected. Regular monitoring and follow-up with healthcare providers are essential to assess the therapy's effectiveness.